TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies

Starting soon

Conditions studied: Hemophilia A, Factor VIII (FVIII)

In brief

This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.

Key facts

Study ID

NCT07692217

Run by

University of Texas Southwestern Medical Center

People needed

60

Starts

2026-07-01

Expected to finish

2033-05-01

Last updated by the study team

2026-07-09

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with moderate or severe HA who are on prophylaxis with either weekly, biweekly, or every 4-weeks emicizumab or weekly efanesoctocog alfa for at least 2 months.
• >6 months of age

You may not qualify if…

• Participants with active FVIII inhibitor (>0.5 BU/mL)
• Presence of an additional bleeding disorder other than hemophilia A

Where it is running

• The University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.